<DOC>
	<DOCNO>NCT02051309</DOCNO>
	<brief_summary>Adult daily smoker motivate quit smoking randomize extended-release guanfacine ( 6mg/day ) placebo enroll 8-week treatment period combine medication brief behavioral support . The investigator hypothesize active dose guanfacine compare placebo increase rate prolong smoke abstinence end 8-week treatment phase .</brief_summary>
	<brief_title>Guanfacine Clinical Trial Smoking Cessation</brief_title>
	<detailed_description />
	<mesh_term>Guanfacine</mesh_term>
	<criteria>Age 1865 Able read , write comprehend English Smoker Able take oral medication willing adhere medication regimen Provide evidence stable living residence last 2 month , reasonable transportation study site , plan move within next 3 month unresolved legal problem Any significant current medical condition would contraindicate smoking Current Diagnostic Statistical Manual Mental Disorders ( DSMIV ) abuse dependence substance , nicotine dependence alcohol abuse Positive test result intake appointment urine drug screen illicit drug Past 30 day use psychoactive drug include anxiolytic antidepressant Women pregnant nursing Suicidal , homicidal evidence current mental illness schizophrenia , bipolar disorder major depression , anxiety disorder Meeting DSMIV criterion current attention deficit hyperactivity disorder ( ADHD ) Individuals currently take medication know effective smoking cessation regular user tobacco product past 30 day Only one member per household participate study Specific exclusion administration guanfacine already specify include : EKG evidence baseline screen clinically significant conduction abnormality arrhythmias Known intolerance guanfacine alpha blocker History fainting , syncopal attack Heart failure myocardial infarction Impaired liver ( indicated aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) &gt; 3x normal ) Renal function ( indicate estimate creatinine clearance &lt; 60cc/min ) Treatment antihypertensive drug alphaadrenergic blocker Use central nervous system depressant ( e.g. , phenothiazine , barbiturate , benzodiazepine ) Use strong cytochrome P450 3A4 ( CYP3A4 ) inhibitor ( e.g. , ketoconazole ) inducer ( e.g. , rifampin ) , consumption grapefruit juice Subjects may donate blood past 8 week involve investigational study involve substantial blood draw medication unknown u</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Smokers</keyword>
	<keyword>Quit Smoking</keyword>
	<keyword>Treatment</keyword>
	<keyword>Guanfacine</keyword>
</DOC>